Crossmark

Treating invasive aspergillosis in patients with hematologic malignancy: diagnostic-driven approach versus empiric therapies

Crossref DOI link: https://doi.org/10.1186/s12879-018-3584-9

Published Online: 2018-12-13

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dib, Rita Wilson

Hachem, Ray Y.

Chaftari, Anne-Marie

Ghaly, Fady

Jiang, Ying

Raad, Issam
Funding

Funding for this research was provided by:

Pfizer (N/A)
License Information

Text and Data Mining valid from 2018-12-01
More Information

Article History

Received: 5 September 2018

Accepted: 3 December 2018

First Online: 13 December 2018

Ethics approval and consent to participate

: The MD Anderson Cancer Center Institutional Review Board has reviewed and approved this retrospective study and a waiver of informed consent was obtained.

: Not applicable.

: The authors declare that they have no competing interests. IR is a consultant and speaker with Pfizer.IR, A-MC and RH are recipients of Pfizer study grants over the last 5 years.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.